



UNIVERSITÄTS KLINIKUM HEIDELBERG

University Hospital Heidelberg

shipping address:
Lab of Complement Diagnostics
Dr. med. Jutta Schröder-Braunstein
Im Neuenheimer Feld 305
Room 220
69120 Heidelberg, Germany

Institute for Immunology,
Acting director: Prof. Dr. A. Roers

Complement Analysis Laboratory Requisition

Ordering Physician:
Full Name, Clinic, Address incl. e-mail and Fax

Patient Surname

First Name

DOB

Gender

Address

HCN:

PAN:

Collection Date

Collection Time

Accession Nr.

Ministry of Health approval included

☐ yes ☐ no

☐ not applicable

Invoice to be sent to:

Report to be sent (if not to ordering physician)

Clinical diagnosis, treatments, special requests:

(Name, Address incl. e-mail and/or Fax)

treatment with C5 Inhibitor: Eculizumab (Soliris®) ☐ yes ☐ no

Ravulizumab (Ultomiris®) ☐ yes ☐ no

current C3 concentration _____ g/l

Complement Analysis

(Information: Phone +49 6221-564026/15, Fax +49 6221-565586/5536, www.klinikum.uni-heidelberg.de/diagnostik.143295.0.html)

Material: ☐ Serum ☐ EDTA-Plasma ☐ other body fluids (specify)

After separation of serum/EDTA-plasma from clot/cells transfer fluid to non-coated vials/tubes, freeze down to -70°C/-20°C and send per courier on dry ice

☐ Complement Status: includes the analysis of global functions of the classical/CH50 and alternative/AP-F pathways (serum), as well as the activation products C3d and sC5b-9 (EDTA-plasma), recommended for general screening and monitoring

Protein Analysis:

☐ C1q

☐ C3

☐ C4

☐ C3d

☐ Factor B

☐ Factor D

☐ Factor H

☐ Factor I

☐ Properdin

☐ MBL (Mannose Bind. Lectin)

Functional Analysis:

☐ Class. Pathway (CH 50)

☐ Altern. Pathway (AP-F)

☐ Lectin Pathway

☐ Titration of individual components (only upon specific request) C1-C9

☐ sC5b-9 (only in EDTA-plasma)

☐ Autoantibodies: ☐ C3 Nephritic Factor (only in serum) ☐ Auto-anti-Factor H ☐ Auto-anti-C1q ☐ Auto-anti-C1 Inhibitor

☐ aHUS - Panel (CH50, AP-F, C3d, sC5b-9, C3, auto-anti-FH)

☐ MPGN - Panel (CH50, AP-F, C3d, sC5b-9, C3, C3 Nephritic Factor)

☐ Nephritic - Panel (CH50, AP-F, C3d, sC5b-9, C3, C3 Nephritic Factor, auto-anti FH)

C5 inhibitor monitoring:

☐ complement inhibition: includes CH50, AP-F, C3d, sC5b-9

serum concentration: ☐ Eculizumab® ☐ Ravulizumab®



Deutsche
Akkreditierungsstelle
D-ML-13060-04-00